

Total Synthesis of Spirotryprostatin B via Asymmetric Nitroolefination


Trusar D. Bagul, Gingipalli Lakshmaiah, Takeo Kawabata, and Kaoru Fuji*

Institute for Chemical Research, Kyoto University, Uji, Kyoto 611-0011, Japan

fuji@scl.kyoto-u.ac.jp

Received November 4, 2001


ABSTRACT



A total synthesis of spirotryprostatin B was accomplished via asymmetric nitroolefination as a key step.

The asymmetric construction of molecules with quaternary carbon stereocenters is a challenging and dynamic area,¹ and this is particularly true for the unabated isolation and structural elucidation of various complex natural products with these stereocenters. We have studied this subject² and have reported a protocol for creating quaternary asymmetric carbon centers via the asymmetric nitroolefination.^{2a,b} This protocol has been applied^{2c–h} to the synthesis of various natural products with quaternary stereocenters: for example, (–)-esermethole,^{2f} (–)-pseudophrynaminol,^{2e,f} (–)-horsifiline,^{2g} etc. We report here the total synthesis of spirotryprostatin B (**1**), a potent antimetabolic agent that was isolated from the fermentation broth of *Aspergillus fumigatus* and has been shown to inhibit progression of the mammalian cell cycle in the G2/M phase at micromolar concentrations.³ The synthetically intriguing structural features of **1** are the C-3 quaternary stereocenter of the spirooxindole, the spiro-pyrrolidine with a diketopiperazine ring system and the

endocyclic conjugated C(8)–C(9) double bond along with the pendent prenyl moiety. Recently, several successful approaches have been reported for the total synthesis of **1** using the oxidative rearrangement of β -carboline,⁴ 1,3-dipolar cycloaddition of azomethine ylides,⁵ and Pd-catalyzed Heck insertion into a conjugated triene followed by an intramolecular nucleophilic attack by amido nitrogen to the resultant η^3 -allyl-Pd intermediate.⁶



Our strategy for the synthesis of **1** involves the enantioselective installation of a C-3 quaternary stereocenter at the


(1) (a) Fuji, K.; *Chem. Rev.* **1993**, *93*, 2037. (b) Corey, E. J.; Guzman-Perez, A. *Angew. Chem., Int. Ed.* **1998**, *37*, 388. (c) Martin, S. F. *Tetrahedron* **1980**, *36*, 419–460.

(2) (a) Fuji, K.; Node, M.; Nagasawa, H.; Naniwa, Y.; Terada, S. *J. Am. Chem. Soc.* **1986**, *108*, 3855. (b) Fuji, K.; Node, M.; Nagasawa, H.; Naniwa, Y.; Taga, T.; Machida, K.; Sntzke, G. *J. Am. Chem. Soc.* **1989**, *111*, 7921. (c) Node, M.; Nagasawa, H.; Fuji, K. *J. Am. Chem. Soc.* **1987**, *109*, 7901. (d) Node, M.; Nagasawa, H.; Fuji, K. *J. Org. Chem.* **1990**, *55*, 517. (e) Fuji, K.; Kawabata, T.; Ohmori, T.; Node, M. *Synlett* **1995**, 367. (f) Fuji, K.; Kawabata, T.; Ohmori, T.; Shang, M.; Node, M. *Heterocycles* **1998**, *47*, 951. (g) Lakshmaiah, G.; Kawabata, T.; Shang, M.; Fuji, K. *J. Org. Chem.* **1999**, *64*, 1699–1704.

(3) (a) Cui, C.-B.; Kakeya, H.; Okada, G.; Onose, R.; Ubukata, M.; Takahashi, I.; Isono, K.; Osada, H. *J. Antibiot.* **1995**, *48*, 1382–1384. (b) Cui, C.-B.; Kakeya, H.; Osada, H. *Tetrahedron* **1996**, *52*, 12651–12666. (d) Cui, C.-B.; Kakeya, H.; Osada, H. *Tetrahedron* **1997**, *53*, 59–72. (e) Cui, C.-B.; Kakeya, H.; Osada, H. *J. Antibiot.* **1996**, *49*, 832–833. (f) Cui, C.-B.; Kakeya, H.; Osada, H. *J. Antibiot.* **1996**, *49*, 534–540.

(4) (a) Edmondson, S.; Danishefsky, S. J. *Angew. Chem., Int. Ed.* **1998**, *37*, 1138–1140. (b) Edmondson, S.; Danishefsky, S. J.; Sepp-Lorenzino, L.; Rosen, N. *J. Am. Chem. Soc.* **1998**, *121*, 2147–2155. (c) Nussbaum, F. V.; Danishefsky, S. J. *Angew. Chem., Int. Ed.* **2000**, *112*, 2175–2178. (d) Wang, H.; Ganesan, A. *J. Org. Chem.* **2000**, *65*, 4685–4693.


outset, using asymmetric nitroolefination of 3-prenyloxindole (Scheme 1). The nitroolefin **5** should act as a precursor to



amino acid surrogate **4**, which on coupling with *L*-proline would lead to dipeptide **3** with all of the requisite functionality. Oxidation of the prenyl unit would provide a route to spiropyrrolidine ring closure to **2**. Incorporation of a conjugated double bond in the spiropyrrolidine unit according to methods described in the literature^{4c} followed by removal of R_2 and cyclization should furnish the target molecule **1**.

Our synthesis began with the preparation of chiral oxindole with a quaternary carbon center, (*S*)-**6** (97% ee), according to our protocol for asymmetric nitroolefination (Scheme 2).^{2e,f} Reduction of **6** with 20% aqueous titanium(III) chloride in the presence of excess ammonium acetate followed by in situ hydrolysis⁷ afforded the aldehyde (*S*)-**7** in 55% yield. Strecker reaction of aldehyde **7** was performed⁸ by treatment with benzylamine followed by trimethylsilyl cyanide to afford the cyano benzylamine **8** (91%) as a 1:1 diastereomeric mixture. Attempted hydrolysis of the cyano group of **8** without protecting the secondary amine resulted in a complicated reaction mixture. Hence, the cyano amine **8** was subjected to Cbz protection to yield **9** in 48% yield with 50% recovery of **8** (96% yield based on recovered **8**). Forcing the reaction to completion resulted in the introduction of a Cbz group at the oxindole nitrogen. Treatment of a methanolic solution of **9** with K_2CO_3 followed by acidification with dilute HCl resulted in the formation of methyl ester **10** in 87% yield (Scheme 2).⁹

Having incorporated the amino ester functionality, our next task was to introduce proline as a peptidic linkage. Thus, it was essential to remove the benzyl and Cbz groups in the presence of ester and a trisubstituted double bond. We found that palladium black (80 wt % of **10**) under hydrogen transfer conditions was suitable for this purpose. A short reaction time (20–30 min) is essential for the chemoselectivity of this reaction, since a longer reaction time results in reduction



^a (a) $TiCl_3$ (20% aqueous, 5.0 equiv), NH_4OAc (5.0 equiv), $MeOH:H_2O$ (4:1), rt, 3 h; (b) i. $BnNH_2$ (1.0 equiv), DCM, rt, 3 h; ii. $TMSCN$ (1.05 equiv), rt, 3 h; (c) $CbzCl$ (1.2 equiv), Et_3N (2.4 equiv), DCM, rt, 12 h; (d) i. K_2CO_3 , $MeOH$, rt, 6 h; ii. aqueous 1 M HCl, rt, 0.5 h; (e) i. Pd black (80 wt %), 5% HCO_2H in $MeOH$, 20 min; ii. *N*-Boc-*L*-proline (1.1 equiv), WSC (1.2 equiv), DMC, 12 h; (f) i. *m*-CPBA (1.1 equiv), DCM, 0 °C, 6 h; ii. $PhSeSePh$ (0.6 equiv), $NaBH_4$ (1.2 equiv), $MeOH$, reflux, 10 h; iii. 30% H_2O_2 (20 equiv), THF, 0 °C, 6 h.

of the double bond. The crude free α -aminoester was subjected to peptide coupling with *N*-Boc-*L*-proline using 1-[3-(dimethylamino)propyl]-3-ethylcarbodiimide hydrochloride (WSC) to give dipeptide **11** in 69% overall yield. For the spiropyrrolidine ring closure, it was essential to activate or functionalize the allylic methylene moiety. It has been reported¹⁰ that allylic alcohols with tethered nitrogenous nucleophiles undergo ring closure upon treatment with a catalytic amount of acid via an intramolecular nucleophilic attack of nitrogen at an allylic carbocation. Hence, the prenyl moiety in **11** was transformed to an allylic alcohol as in **12** in 85% yield, according to a protocol reported by Sharpless and Lauer.¹¹

Treatment of **12** with 10 mol % of *p*-toluenesulfonic acid in acetonitrile under reflux for 15 min gave the key spirocyclic intermediates as a 1:1 mixture of two diastereomers **13** and **14** in 47% yield with 50% recovery of **12** (94% yield based on recovered **12**) (Scheme 3). A longer reaction time to achieve complete transformation resulted in significant

(5) Sebahar, P. R.; Williams, R. M. *J. Am. Chem. Soc.* **2000**, *122*, 5666–5667.

(6) Overman, L. E.; Rosen, M. D. *Angew. Chem., Int. Ed.* **2000**, *112*, 4569–4599.


(7) McMurry, J. E.; Melton, J. *J. Org. Chem.* **1973**, *38*, 4367–4373.

(8) Ojima, I.; Inaba, S.; Nakatsugawa, K.; Nagai, Y. *Chem. Lett.* **1975**, 331–334.

(9) (a) Wenger, M. *Helv. Chim. Acta* **1983**, *66*, 2308–2321. (b) Zandorgon, P.; Brusse, J.; Gen, A. V. D. *Tetrahedron: Asymmetry* **1992**, *3*, 769–774.

(10) Harrington, P. J.; Hegedus, L. S.; McDaniel, K. F. *J. Am. Chem. Soc.* **1987**, *109*, 4335–4338.

(11) Sharpless, K. B.; Lauer, R. F. *J. Am. Chem. Soc.* **1973**, *95*, 2697–2699.


Scheme 3^a

^a (a) *p*-TSA (10 mol %), CH₃CN, reflux, 25 min; (b) i. 4 M HCl in dioxan, 0 °C, 30 min; ii. Et₃N, DCM, rt, 4–6 h. Arrows in **15** and **16** denote the observed NOEs.

deprotection of the Boc moiety, and hence the reaction was stopped at 50% conversion. Stereochemical assignment of **13** and **14** was unsuccessful because of the broadening of NMR peaks due to amide *E/Z* isomerization. Thus, the stereochemistry of **13** and **14** was determined through their transformation to diketopiperazine derivatives **15** (91%) and **16** (89%), respectively. The configurations at C(9) and C(18) were assigned using ¹H–¹H NOESY, and NOE experiments based on the known (*S*)-configuration at both the C(3) and C(12) stereocenters. Thus, diastereomer **13** was found to have the desired *S* configuration at C(18) in its transformation to **1**.

The final transformations required for the synthesis of **1** are the introduction of a double bond in conjugation to the ester in **13** and cyclization of the diketopiperazine ring. During our progress toward the synthesis of **1**, Nussbaum and Danishefsky reported^{4c} a total synthesis of **1** via a

mixture of four diastereomers at the C(3) and C(18) stereocenters of **14**. Thus, the synthesis of diastereomerically pure **13** with the desired configuration at C(18) and C(3) itself represents a formal total synthesis of **1**. To make sure that this particular diastereomer leads to **1**, it was subjected to the reported protocol for the introduction of a double bond. This procedure led to an inseparable mixture of multiple products and hence the crude mixture was subjected to diketopiperazine ring formation by deprotection of the Boc group with 4 M HCl solution in dioxan followed by cyclization with triethylamine. Isolation and purification revealed the presence of the desired natural product **1** (21%) along with two diastereomeric dihydrospirotryprostatin B analogues, **15** (10%) and **18** (23%),^{4b,d} and the unexpected hemiaminal **17** (9%), which has also been shown to be a key precursor to **1** by Ganesan and Wang.^{4d} The spectral characteristics of **1**, **17**, and **18** are identical to those reported in the literature (Scheme 4).^{4–6}

Scheme 4^a

^a (a) i. LiHMDS, THF, 0 °C, 30 min; ii. PhSeCl, THF, 0 °C, 2 h; iii. DMDO, THF, 0 °C, 4 h; iv. 4 M HCl in dioxan, 0 °C, 30 min; v. Et₃N, DCM, 4 h. DMDO = dimethyldioxirane. LiHMDS = lithium hexamethyldisilazide.

Acknowledgment. We gratefully acknowledge the financial support to T.D.B. and G.L. by JSPS, Japan Society for the Promotion of Science.

Supporting Information Available: Experimental procedures and characterization data for compounds **7**–**17**. This material is available free of charge via Internet at <http://pubs.acs.org>.

OL016995S